Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

decitabine

A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It is a type of antimetabolite. [from NCI]

MedGen UID:
25072
Concept ID:
C0049065
Pharmacologic Substance
2.

DNA Methylation

Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor. [from MeSH]

MedGen UID:
138191
Concept ID:
C0376452
Molecular Function
3.

Methylation

A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body. [from NCI]

MedGen UID:
44400
Concept ID:
C0025723
Molecular Function
4.

Malignant Neoplasm

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body. . Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, biologic therapy, or stem cell transplantation. . NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
14297
Concept ID:
C0006826
Neoplastic Process
5.

Leukemia

Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including: -Acute lymphocytic leukemia. -Acute myeloid leukemia. -Chronic lymphocytic leukemia. -Chronic myeloid leukemia. Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; childen with leukemia most often have an acute type.Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
9725
Concept ID:
C0023418
Neoplastic Process
6.

Acute myeloid leukemia

A form of leukemia characterized by overproduction of an early myeloid cell. [from HPO]

MedGen UID:
505691
Concept ID:
CN004254
Finding
7.

Leukemia

A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [from HPO]

MedGen UID:
505002
Concept ID:
CN001727
Finding
8.

Error occurred: cannot get document summary

ID:
442132

9.

Error occurred: cannot get document summary

ID:
430295

10.

Disease Response

The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression. [from NCI]

MedGen UID:
309976
Concept ID:
C1704632
Finding
11.

Biphasic Pattern

MedGen UID:
272369
Concept ID:
C1332555
Finding
12.

Error occurred: cannot get document summary

ID:
272128

13.

Proliferation

Growth and reproduction of new similar forms, e.g. cells, buds, or offspring. [from NCI]

MedGen UID:
137720
Concept ID:
C0334094
Pathologic Function
14.

cytotoxicity

The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells. In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed. [from NCI]

MedGen UID:
108579
Concept ID:
C0596402
Cell or Molecular Dysfunction
15.

Acute

Symptoms or signs that begin and worsen quickly; not chronic. [from NCI]

MedGen UID:
61381
Concept ID:
C0205178
16.

Immunoglobulins

there are two types of polypeptide chains responsible for the biological and immunological properties of the different immunoglobulins, the heavy chain and the light chain; they are linked by covalent and non-covalent forces to give a four-chain Y-shaped structure based on pairs of identical heavy and light chains; each chain consists of a variable region and a constant region which are coded for by different genes; some immunoglobulin classes occur as polymers of this basic monomer. [from CRISP]

MedGen UID:
43841
Concept ID:
C0021027
Pharmacologic Substance
17.

Lysis

Tissue structure disintegration and destruction due to action of endogenous or/and exogenous lytic substances which include but not limited to naturally occuring or laboratory designed proteolytic enzymes, glycosidases, detergents, pore-forming proteins, immune complexes, etc. Tissue lysis plays role in pathogenesis of a number of conditions e.g. protozoal infections, ischemic tissue injury, and autoimmune disorders. It is also used as a basis for non-surgical treatment modality to remove or minimize presence of abnormal tissue, e.g. adhesions. [from NCI]

MedGen UID:
9837
Concept ID:
C0024348
Pathologic Function
18.

AML - Acute myeloid leukemia

Familial acute myeloid leukemia (AML) with mutated CEBPA is defined as AML in which a germline CEBPA mutation is present in a family in which multiple individuals have AML. In contrast, sporadic AML with mutated CEBPA is defined as AML in which a CEBPA mutation is identified in somatic (i.e., leukemic) cells but not in germline (i.e., non-leukemic) cells. Too few persons with familial AML with mutated CEBPA have been reported to be certain about the natural history of the disease. The age of onset of familial AML with mutated CEBPA appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age four years and older than age 50 years. The prognosis of individuals with familial AML with mutated CEBPA appears to be favorable (~50%-65% overall survival) compared to the ~25%-40% overall survival of those who have normal karyotype AML but no germline CEPBA mutation. Individuals with familial AML with mutated CEBPA who have been cured of their initial disease may be at greater risk of developing additional malignant clones than persons with sporadic disease. [from GeneReviews]

MedGen UID:
9730
Concept ID:
C0023467
Neoplastic Process
19.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function
20.

Acute Myeloid Leukemia with Maturation

An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. AML with the t(8;21) is usually AML with maturation. This type of AML frequently responds to aggressive therapy. (WHO, 2001) [from NCI]

MedGen UID:
361829
Concept ID:
C1879321
Neoplastic Process

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...